Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 70
Filter
1.
Water Sci Technol ; 54(3): 225-30, 2006.
Article in English | MEDLINE | ID: mdl-17037157

ABSTRACT

A two-month survey was conducted in order to evaluate the effects of rainfall on the fate of microorganisms in seawater in the Tokyo Bay, Japan. The seawater sample (1,000 mL) was applied to a method to concentrate virus, followed by a quantification of human adenoviruses using the real-time PCR. Total coliforms and E. coli, which were determined by the colony forming method, were detected in all 47 seawater samples, while human adenoviruses were detected in 38 (81%) of the samples. The concentration of tested microorganisms showed 1-2 log units increase after rainfall events, followed by the gradual decrease to the level before the rainfall within a few days.


Subject(s)
Adenoviridae/isolation & purification , Enterobacteriaceae/isolation & purification , Rain , Seawater/microbiology , Water Microbiology , Base Sequence , Colony Count, Microbial , DNA Primers , Japan , Polymerase Chain Reaction , Seawater/virology
2.
Water Sci Technol ; 52(9): 107-14, 2005.
Article in English | MEDLINE | ID: mdl-16445179

ABSTRACT

Dynamic changes in the chemical environment in the bottom of overlying water and microbial community structure in trench and flat seabed sediments were evaluated during summer and autumn in Tokyo Bay, Japan, to elucidate the response of microbial community changes as a consequence of dredging activity. Quinone profile analysis was performed to evaluate the changes in microbial community structure in the sediments. Bottom shape and location of each station affected the chemical environment of the overlying water. The trench bottom shape had longer anoxic conditions than the flat bottom shape. Nitrogen and phosphorus concentrations affected the microbial density in the sediment. During anoxic conditions, the ubiquinone/menaquinone ratio (UQ/MK) was less than unity and increased with rising dissolved oxygen (DO) concentrations. The dominant quinone species in the trench and flat seabed sediments were MK with 6 and 7 isoprene units (MK-6 and MK-7) and UQ with 8 and 9 isoprene units (UQ-8 and UQ-9). MK-6 and UQ-8 containing bacteria might have a great influence on the sulfur cycle of the aquatic ecosystem. While, MK-7 and UQ-9 containing bacteria correlated with the deposition of phototropic bacteria cells onto the seabed sediment. The trench bottom shape contained higher concentrations of MK-6, MK-7, UQ-8 and UQ-9, especially during summer.


Subject(s)
Geologic Sediments/microbiology , Water Microbiology , Bacteria/growth & development , Environmental Monitoring , Facility Design and Construction , Geologic Sediments/chemistry , Japan , Oxygen/analysis , Population Dynamics , Seasons
3.
Br J Cancer ; 86(2): 222-5, 2002 Jan 21.
Article in English | MEDLINE | ID: mdl-11870510

ABSTRACT

We have investigated dihydropyrimidine dehydrogenase expression as a prognostic marker in breast cancer. A total of 119 women with breast cancer undergoing surgery between 1985 and 1996 were included in this study. Eighty-seven patients were treated with postoperative chemotherapy including 5-fluorouracil or 5-fluorouracil derivatives. Fifty-nine (50%) of 119 patients were determined to be immunostaining-positive for dihydropyrimidine dehydrogenase. There was no significant difference between dihydropyrimidine dehydrogenase staining and tumour size, lymph node status, clinical stage, oestrogen receptor status, histologic grade, or 5-fluorouracil administration. When evaluated in patients treated with 5-fluorouracil or 5-fluorouracil derivatives, patients with dihydropyrimidine dehydrogenase-positive tumours had a significantly (P<0.05) poorer disease-free survival compared to those with dihydropyrimidine dehydrogenase-negative tumour. No conclusion can be drawn about the prognostic impact of dihydropyrimidine dehydrogenase status in patients who were not treated with 5-fluorouracil regimes due to the small number of such cases in this series. Lymph node and dihydropyrimidine dehydrogenase status were independent prognostic factors for disease-free survival, and lymph node status for overall survival using multivariate analysis. In conclusion, dihydropyrimidine dehydrogenase is a possible prognostic factor in patients with breast cancer treated with 5-fluorouracil or 5-fluorouracil derivatives.


Subject(s)
Antineoplastic Agents/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/enzymology , Gene Expression Regulation, Neoplastic , Oxidoreductases/biosynthesis , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor , Breast Neoplasms/pathology , Chemotherapy, Adjuvant , Dihydrouracil Dehydrogenase (NADP) , Disease-Free Survival , Female , Fluorouracil/administration & dosage , Humans , Immunohistochemistry , Lymphatic Metastasis , Middle Aged , Neoplasm Staging , Prognosis
4.
Oncol Rep ; 9(2): 375-8, 2002.
Article in English | MEDLINE | ID: mdl-11836611

ABSTRACT

It is important to determine which factors are predictive for the prognosis of patients treated with breast conserving surgery (BCS) and radiation therapy (RT) in order to make a decision as to the adjuvant treatment. Although estrogen receptor (ER) is known to be a predictive marker for antiestrogens in breast cancer, the prognostic effect of hormone receptors has not been fully analyzed in Japanese breast cancer patients treated with BCS and RT. A total of 153 breast cancer patients having up to three positive nodes in the axilla as identified histologically and treated with both BCS and RT with or without systemic therapy were enrolled in this study. All tumors were measured for ER and progesterone receptor (PR) using ligand-binding assay (LBA). ER was inversely related to patients' age, however, PR was not related to any clinical features. When ER was classified into negative, weakly positive and strongly positive categories, with cut-off levels of zero and 50 fmol/mg protein, the relapse-free survival (RFS) was significantly better in patients with tumors having strongly positive ER than in patients with tumors having negative ER. Multivariate analysis revealed that ER as well as nodal status, was an independent predictive factor for RFS, however, PR was not. As a result, we believe that ER measured by LBA is valuable for predicting prognosis of early-stage breast cancer patients treated with BCS and RT.


Subject(s)
Adenocarcinoma, Scirrhous/therapy , Adenocarcinoma/therapy , Biomarkers, Tumor/metabolism , Breast Neoplasms/therapy , Receptors, Estrogen/metabolism , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Adenocarcinoma, Scirrhous/metabolism , Adenocarcinoma, Scirrhous/pathology , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Chemotherapy, Adjuvant , Combined Modality Therapy , Disease-Free Survival , Female , Humans , Immunoenzyme Techniques , Ligands , Mastectomy, Segmental , Middle Aged , Neoplasm Staging , Predictive Value of Tests , Prognosis , Radiotherapy , Receptors, Progesterone/metabolism
5.
Anticancer Res ; 21(4B): 2963-7, 2001.
Article in English | MEDLINE | ID: mdl-11712794

ABSTRACT

The purpose of this study was to compare the results of 133 cases (131 patients) of subcutaneous mastectomy with axillary dissection between 1983 and 1999 and 910 cases of radical mastectomy during the same period. The median follow-up period of the subcutaneous mastectomy group and the radical mastectomy group were 66 months and 81 months, respectively. The age at operation was significantly (p<0.01) younger in the subcutaneous mastectomy group than in the radical mastectomy group and the clinical stage was significantly (p<0.01) earlier. Lymph node metastasis was significantly (p<0.01) higher in the radical mastectomy than in the subcutaneous mastectomy group. There was no difference in ER status between the two groups. There was local recurrence in 5 (3.8%) members of the subcutaneous mastectomy group and in 12 (1.3%) members of the radical mastectomy group. There was no difference in disease-free survival and overall survival between the two groups. Divided into two subgroups by lymph node status, there was no difference in disease-free survival and overall survival between the two groups. Local recurrence occurred more frequently (p<0.05) in the subcutaneous mastectomy group, however, than in the radical mastectomy group when no lymph node metastasis was found. Multivariate analysis using the Cox hazard model showed that operation method and lymph node status were independent prognostic factors for local recurrence, whereas, lymph node status and ER status were independent prognostic factors of disease-free survival. In conclusion, subcutaneous mastectomy presents a risk factor for local recurrence, but the survival rate of the subcutaneous mastectomy group is as favourable as the radical mastectomy group.


Subject(s)
Breast Neoplasms/surgery , Mastectomy, Radical , Mastectomy, Subcutaneous , Adult , Age Factors , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Axilla , Breast Neoplasms/chemistry , Breast Neoplasms/drug therapy , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Chemotherapy, Adjuvant , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Disease-Free Survival , Drug Combinations , Female , Fluorouracil/administration & dosage , Humans , Japan/epidemiology , Life Tables , Lymph Node Excision , Lymphatic Metastasis , Middle Aged , Mitomycin/administration & dosage , Neoplasm Proteins/analysis , Neoplasm Recurrence, Local , Prednisolone/administration & dosage , Proportional Hazards Models , Receptors, Estrogen/analysis , Retrospective Studies , Risk Factors , Survival Analysis , Tamoxifen/administration & dosage , Tegafur/administration & dosage , Treatment Outcome , Uracil/administration & dosage
6.
J Heart Lung Transplant ; 20(5): 568-74, 2001 May.
Article in English | MEDLINE | ID: mdl-11343984

ABSTRACT

BACKGROUND: FR167653 is a potent suppressant of tumor necrosis factor (TNF)-alpha and interleukin-1 (IL-1) production, and was shown to attenuate ischemia and reperfusion (I/R) organ injury in our previous experiment. Because p38 mitogen-activated protein (MAP) kinase has been reported to regulate the production of TNF-alpha and IL-1, we examined the effects of FR167653 in the rat lung I/R model and determined the expression and activation of p38 MAP kinase. METHODS: Experiment 1: After 1 hour of ischemia, p38 MAP kinase, phosphorylated p38 MAP kinase (active form), histologic changes of the lung, and serum levels of TNF-alpha and IL-1beta were examined. Experiment 2: After 2 hours of reperfusion, arterial oxygen content (PaO(2)) and saturation (SaO(2)), serum TNF-alpha and IL-1beta levels, and histologic changes in the lung were examined. Rats were divided into three groups in Experiment 1. In the control group, a saline solution was administered and, in the FR group, 0.1 mg/kg per hour of FR167653 was administered, intravenously throughout the experiment, beginning 30 minutes before ischemia. In the non-ischemic group, samples were taken soon after thoracotomy. The rats were divided into control and FR groups in Experiment 2. RESULTS: Experiment 1: One hour of ischemia induced almost no changes in the lung or serum cytokine levels. Meanwhile, FR167653 markedly attenuated the expression of phosphorylated p38 MAP kinase. Experiment 2: SaO(2) and PaO(2) were improved, serum cytokines were lower, and lung damage was less extensive in the FR group than in the control group. CONCLUSION: FR167653 attenuates I/R injury of the lung and this attenuation is associated with suppression of p38 MAP kinase activation.


Subject(s)
Immunosuppressive Agents/pharmacology , Ischemia/prevention & control , Lung/blood supply , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinases/analysis , Pyrazoles/pharmacology , Pyridines/pharmacology , Reperfusion Injury/prevention & control , Animals , Cytokines/drug effects , Interleukin-1/blood , Male , Models, Animal , Rats , Rats, Wistar , Tumor Necrosis Factor-alpha/analysis , Tumor Necrosis Factor-alpha/drug effects , p38 Mitogen-Activated Protein Kinases
7.
Crit Care Med ; 29(3): 628-34, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11373433

ABSTRACT

OBJECTIVE: Sepsis is a major cause of adult respiratory distress syndrome. In this study, we evaluated the effect of FR167653, which is a potent suppressant of tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 production, on lipopolysaccharide (LPS)-induced lung injury and lethality in rats, and we examined the involvement of p38 mitogen-activated protein (MAP) kinase in the action of FR167653. DESIGN: Prospective, randomized study. SETTING: Animal research facility in a university. SUBJECTS: Male Sprague-Dawley rats weighing 200-270 g. INTERVENTIONS: All the animals were assigned to one of the following four groups: control group, FR-only group, LPS-only group, and LPS/FR group. Animals in the LPS-only and LPS/FR groups received 6 mg/kg of LPS intravenously. The animals in the FR-only and LPS/FR groups also received an infusion of FR167653 at 0.2 mg x kg(-1) x hr(-1), commencing 30 mins before the LPS (or vehicle) injection and continuing for 5.5 hrs. MEASUREMENTS AND MAIN RESULTS: LPS significantly induced the accumulation of pulmonary neutrophils and lung edema, both of which were significantly attenuated by treatment with FR167653. FR167653 also significantly decreased the LPS-induced lethality. Histologically, tissue damage was milder in the LPS/FR group than in the LPS-only group. Serum concentrations of TNF-alpha and IL-1beta and plasma concentrations of thromboxane B2 were all suppressed in the LPS/FR group compared with the LPS-only group. Western blot analysis revealed that FR167653 inhibited the phosphorylation of p38 MAP kinase in lung tissues. CONCLUSIONS: FR167653 administration decreased serum TNF-alpha and IL-1beta concentrations, which was associated with decreased lung injury and lethality. The mechanism responsible for the decreased TNF-alpha and IL-1 may be related to the inhibitory effect of FR167653 on p38 MAP kinase activation.


Subject(s)
Disease Models, Animal , Escherichia coli Infections/complications , Escherichia coli , Immunosuppressive Agents/therapeutic use , Interleukin-1/antagonists & inhibitors , Lipopolysaccharides , Mitogen-Activated Protein Kinases/drug effects , Pyrazoles/therapeutic use , Pyridines/therapeutic use , Respiratory Distress Syndrome/drug therapy , Respiratory Distress Syndrome/microbiology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Animals , Drug Evaluation, Preclinical , Immunosuppressive Agents/chemistry , Immunosuppressive Agents/immunology , Interleukin-1/blood , Interleukin-1/immunology , Lung/chemistry , Male , Mitogen-Activated Protein Kinases/analysis , Prospective Studies , Pyrazoles/chemistry , Pyrazoles/immunology , Pyridines/chemistry , Pyridines/immunology , Random Allocation , Rats , Rats, Sprague-Dawley , Respiratory Distress Syndrome/immunology , Respiratory Distress Syndrome/metabolism , Respiratory Distress Syndrome/mortality , Survival Analysis , Thromboxane B2/blood , Time Factors , Tumor Necrosis Factor-alpha/drug effects , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha/metabolism , p38 Mitogen-Activated Protein Kinases
8.
Surg Today ; 31(2): 149-51, 2001.
Article in English | MEDLINE | ID: mdl-11291709

ABSTRACT

We report herein the case of a 40-year-old man with grade II invasive ductal carcinoma of the breast (pT1, pN0, M0: stage I) in whom a recurrence developed shortly after completion of a 2-year course of tamoxifen and 5-fluorouracil therapy following a mastectomy. Although the metastatic tumor was estrogen receptor-positive, hormone therapy combined with chemotherapy had no significant effect on tumor growth, and the patient died from disseminated tumors 2 years 6 months after completion of the adjuvant therapy. It is noteworthy that the circulating estradiol level increased from 18.0 to 892.3 pg/ml during the period of tumor progression and dissemination. We interpret these findings as an indication of high aromatase activity in the metastatic tumors. We suggest that extending tamoxifen treatment to 5 years or longer be recommended for the standard adjuvant hormone therapy of male breast cancer to prevent the early recurrence of hormone-responsive disease.


Subject(s)
Antineoplastic Agents, Hormonal/pharmacology , Breast Neoplasms, Male/pathology , Carcinoma, Ductal, Breast/pathology , Estradiol/blood , Neoplasm Recurrence, Local , Tamoxifen/pharmacology , Adult , Antimetabolites, Antineoplastic/therapeutic use , Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms, Male/drug therapy , Breast Neoplasms, Male/surgery , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Ductal, Breast/surgery , Drug Administration Schedule , Drug Resistance, Neoplasm , Drug Therapy, Combination , Fatal Outcome , Fluorouracil/therapeutic use , Humans , Male , Tamoxifen/therapeutic use , Time Factors
9.
Oncol Rep ; 8(3): 543-6, 2001.
Article in English | MEDLINE | ID: mdl-11295077

ABSTRACT

The effect of a combined therapy of medroxyprogesterone acetate (MPA) and 5-fluorouracil (5-FU) on tumor size, pyrimidine nucleoside phosphorylase (PyNPase) activity, and thymidylate synthetase (TS) activity was examined in Sprague-Dawley (SD) rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors. MPA augmented the antitumor activity of 5-FU and protected against body weight-loss due to 5-FU administration. PyNPase activity of both the MPA group and the MPA+5-FU group tended to increase compared with that of the 5-FU alone group. TS inhibition levels in the MPA+5-FU group tended to increase compared with those in the 5-FU alone group. These results indicate that MPA tended to augment antitumor activity of 5-FU and to reduce the side effects caused by 5-FU.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Antineoplastic Agents, Hormonal/therapeutic use , Fluorouracil/therapeutic use , Mammary Neoplasms, Experimental/drug therapy , Medroxyprogesterone Acetate/therapeutic use , Pentosyltransferases/metabolism , Thymidylate Synthase/metabolism , 9,10-Dimethyl-1,2-benzanthracene , Animals , Body Weight , Drug Therapy, Combination , Female , Mammary Neoplasms, Experimental/chemically induced , Mammary Neoplasms, Experimental/enzymology , Pyrimidine Phosphorylases , Rats , Rats, Sprague-Dawley
11.
Breast Cancer ; 8(1): 52-7, 2001.
Article in English | MEDLINE | ID: mdl-11180766

ABSTRACT

OBJECTIVE: To assess recurrence of breast cancer following local excision alone for ductal carcinoma in situ. METHODS: Eighteen patients who received complete resection for noninvasive ductal carcinoma between 1982 and 1997 were investigated in this study. The mean age of the patients was 45 (29-78) years old. The initial presentation was a clinically palpable tumor in 4 patients, nipple discharge in 6, and microcalcification on mammograms in 8. Patients with palpable tumor underwent wide excision with at least a 2-cm free margin. Patients whose mammograms showed microcalcification underwent lumpectomy, and those who showed nipple discharge underwent duct-lobular segmentectomy. Five patients who underwent lymph node dissection up to level I or II had no lymph node metastasis. The mean follow-up period was 86 months. RESULTS: Local recurrence in the conserved breast was seen in five (27.8%) of 18 patients. The actuarial five-year event-free survival was 76.2%. The histological type of the recurrent tumor was ductal carcinoma in situ in three patients and invasive carcinoma in two. There was no difference in age at initial operation or histological subtype between patients with and without recurrent disease, but patients presenting with nipple discharge initially had a significantly shorter ipsilateral disease-free interval than those presenting with tumor or microcalcification on mammograms. All patients with local recurrence in the conserved breast were treated with breast-conserving surgery or subcutaneous mastectomy. CONCLUSION: Local recurrence frequently occurs in patients presenting with nipple discharge treated by duct-lobular segmentectomy for noninvasive ductal carcinoma. Either wide excision with a larger free margin or adjuvant radiation therapy following duct-lobular segmentectomy should be considered for these patients.


Subject(s)
Breast Neoplasms/pathology , Carcinoma, Intraductal, Noninfiltrating/pathology , Mastectomy, Segmental , Neoplasm Recurrence, Local/pathology , Adult , Aged , Biopsy , Breast Neoplasms/surgery , Carcinoma, Intraductal, Noninfiltrating/surgery , Disease-Free Survival , Female , Follow-Up Studies , Humans , Mammography , Middle Aged , Prognosis , Risk Factors
12.
Oncol Rep ; 7(6): 1333-8, 2000.
Article in English | MEDLINE | ID: mdl-11032939

ABSTRACT

The serum concentration of pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) was examined in 83 patients with metastatic breast cancer. ICTP levels were significantly higher in patients with bone metastases than in those without bone metastasis. In patients with bone metastasis, significantly higher ICTP levels were observed in those with multiple lesions than in those with a solitary lesion and these levels reflected therapeutic response. Sequential monitoring of ICTP revealed that this elevation was correlated with disease progression. Combined with imaging studies, monitoring of ICTP appears to offer additional information for detection of bone metastasis and evaluation of therapeutic response to bone metastasis.


Subject(s)
Biomarkers, Tumor/blood , Breast Neoplasms/blood , Collagen/blood , Peptides/blood , Adult , Aged , Aged, 80 and over , Bone Neoplasms/blood , Bone Neoplasms/secondary , Bone Neoplasms/therapy , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Collagen Type I , Female , Humans , Middle Aged , Monitoring, Physiologic , Neoplasm Metastasis
14.
Jpn J Clin Oncol ; 30(6): 279-82, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10939434

ABSTRACT

A case of primary squamous cell carcinoma of the breast during lactation is reported. The patient was a 32-year-old woman, in post-partum lactating 18 months after delivery, who was referred to our hospital following detection of a lump in her left breast during physical examination in mass screening for breast cancer. The tumor, palpated in the upper outer quadrant of the left breast, was firm, well-defined and 2.8 x 2.6 cm in size. Ultrasonograms identified an irregular-shaped hypoechoic lesion and mammograms revealed a well-defined, circumscribed tumor. Based on these findings, breast cancer was suspected and an excisional biopsy was performed. The resected specimen was a firm, solid and circumscribed tumor with central hemorrhage. Microscopic findings demonstrated that the tumor consisted of an invasive ductal carcinoma with marked squamous metaplasia, such as keratinization and squamo-columnar junction. Breast-conserving surgery was performed and no lymph node involvement was noted. Both estrogen and progesterone receptors of the tumor were negative. Generally, the size of both squamous cell carcinoma and carcinoma during the lactation period tends to be larger than ordinary carcinomas. In this case, the cancerous lesion was detected at a relatively early stage. Although the cancerous lesion was detected at a relatively early stage and no lymph node involvement was noted, lung metastases occurred within 12 months of the surgery. Malignant potential is generally considered to be high in cases of squamous cell carcinoma of the breast with lactation and thus intensive treatment potentially resulting in severe side effects was considered to be necessary for this patient.


Subject(s)
Breast Neoplasms/etiology , Carcinoma, Squamous Cell/etiology , Lactation , Adult , Breast Neoplasms/pathology , Breast Neoplasms/physiopathology , Carcinoma, Squamous Cell/physiopathology , Carcinoma, Squamous Cell/secondary , Female , Humans , Lung Neoplasms/secondary
15.
Cancer Lett ; 156(1): 109-16, 2000 Aug 01.
Article in English | MEDLINE | ID: mdl-10840166

ABSTRACT

The aim of this study was to determine whether microvessel density (MVD) could add useful information in predicting the prognosis of breast cancer patients. In our study, MVD was calculated by counting microvessels per x200 field in the highest neovascularized area of the tumor (highest microvessel count, HMC). HMC significantly increased according to the increased number of positive nodes. Higher HMC significantly correlated with worse relapse-free survival (RFS) of patients with negative node, one to three positive nodes in the axilla or with stage I and II tumors. HMC, however, was not predictive for RFS of patients with four or more positive nodes or with stage III tumors. Multivariate analysis revealed that HMC was second only to nodal status and tumor size as being predictive for RFS. These results suggest that HMC could be used in selection of patients with early-stage breast cancer who are at high risk for having occult metastasis.


Subject(s)
Breast Neoplasms/blood supply , Neovascularization, Pathologic/mortality , Adult , Aged , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Female , Humans , Middle Aged , Neoplasm Staging , Prognosis
16.
J Heart Lung Transplant ; 19(4): 377-83, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10775819

ABSTRACT

BACKGROUND: A novel synthesized organic compound, FR167653, has been characterized as a potent suppressant of interleukin-1 and tumor necrosis factor-alpha. We designed this experimental study to evaluate the effect of FR167653 on ischemia-reperfusion injury of the rat lung. METHODS: Following general anesthesia, the left bronchus, pulmonary artery and vein were clamped for 1 hour. FR167653 was administered continuously beginning 30 minutes before the onset of ischemia and extending for 2 hours after reperfusion. Thirty-eight Wistar rats were divided into 4 groups according to the dose of FR167653 at the rate of 0.1, 0.05 and 0.025 mg/kg/hr in each group. After the optimal dose was obtained from the result of 1-week survival rate, the group with the optimal dose was compared with a control group by using such parameters as arterial oxygen saturation (SaO(2)), arterial oxygen tension (PaO(2)), cytokines, the expression of p38 MAP kinase and histologic study. RESULTS: Survival rate of the group received FR at the rate of 0.1 mg/kg/hr (FR0.1 group) was best among the 4 groups. SaO(2) levels and PaO(2) levels after 2-hour of reperfusion were significantly (p < 0.05, respectively) higher in the FR0.1 group than in the control group. After 2-hour reperfusion, IL-1 beta was lower in the FR0.1 group than in the control group, and the expression of p38 MAP kinase was reduced in the FR0.1 group compared with the control group. In histologic study after 2-hour of reperfusion, alveolar damage with edema and interstitial thickening localized along the alveolar duct were observed in the control group, whereas these findings were remarkably less evident in the FR0.1 group. CONCLUSIONS: We concluded that FR167653 ameliorates ischemia-reperfusion injury of the lung and may inhibit the production of proinflammatory cytokines by means of the inhibition of p38 MAP kinase.


Subject(s)
Lung/blood supply , Lung/drug effects , Pyrazoles/pharmacology , Pyridines/pharmacology , Reperfusion Injury/drug therapy , Animals , Base Sequence , Cytokines/analysis , Disease Models, Animal , Dose-Response Relationship, Drug , Infusions, Intravenous , Lung/metabolism , Male , Molecular Sequence Data , Oxygen Consumption , Polymerase Chain Reaction , Rats , Rats, Wistar , Reference Values , Regional Blood Flow/drug effects , Reperfusion Injury/metabolism , Reperfusion Injury/mortality , Statistics, Nonparametric , Survival Rate
17.
Oncol Rep ; 7(2): 295-8, 2000.
Article in English | MEDLINE | ID: mdl-10671674

ABSTRACT

One hundred and seventy patients received breast-conserving therapy in the Second Department of Surgery, Gunma University School of Medicine. Six (3.5%) out of the 170 patients showed breast recurrence. We investigated the breast recurrent cases clinicopathologically. The age at the initial operation ranged from 38 to 78 (mean 57) years. One patient was clinical stage I and the others were clinical stage II. Surgical margin at the initial operation was negative in two patients and positive in four. Histological type was invasive ductal cancer in all cases. Three patients had lymph node involvement. The interval from the initial operation to breast recurrence ranged from 19 to 68 months. Five cases were nodular type and one was diffuse type of breast recurrence. Histological type of breast recurrence was the same as the initial one. We performed salvage surgery for all breast recurrent patients, mastectomy for four patients and local resection for two. One patient who showed diffuse type of recurrence could not be controlled with any surgical treatment, and later died of breast cancer. We investigated the expression of estrogen receptor, progesterone receptor, pS2, c-erbB-2 and p53 on both initial and recurrent specimens of the six patients. The expression of each protein on the recurrent specimens was the same as the initial one. We conclude that breast recurrence after breast-conserving therapy has its origin in the residue of cancer cells at the initial operation, even if surgical margins are histopathologically negative.


Subject(s)
Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Proteins/metabolism , Receptor, ErbB-2/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Tumor Suppressor Protein p53/metabolism , Adult , Aged , Breast Neoplasms/surgery , Female , Humans , Immunohistochemistry , Middle Aged , Recurrence , Trefoil Factor-1 , Tumor Suppressor Proteins
18.
Oncol Rep ; 7(1): 135-40, 2000.
Article in English | MEDLINE | ID: mdl-10601607

ABSTRACT

The purpose of this study was to investigate whether tamoxifen (TAM) treatment causes a downregulation of estrogen receptor (ER) and whether TAM induces epidermal growth factor receptor-1 (EGFR). We investigated the expression of ER and EGFR after the treatment of TAM in MCF-7 tumors grown in athymic mice under high and low estrogen environments. MCF-7 tumors were grown in ovariectomized athymic mice by implanting a sustained release 17beta-estradiol (E2) pellet. The E2 pellets were removed after 3 weeks of E2 treatment. Animals were then divided into the following 4 groups: i) an E2 (0. 72 mg/pellet) pellet [E2(+)]; ii) an E2 and a TAM (5 mg/pellet) pellets [E2(+)TAM]; iii) no treatment [E2(-)]; iv) a TAM pellet [E2(-)TAM]. A significant reduction in tumor size was observed in the estrogen-depleted group [E2(-) and E2(-)TAM] compared with the estrogen-completed group [E2(+) and E2(+)TAM]. TAM inhibited estrogen-stimulated growth in the estrogen-completed mice. No additional reduction of the tumor by TAM was observed in the estrogen-depleted mice. Both ER and EGFR protein levels in the tumors of the estrogen-depleted mice were higher than in the estrogen-completed mice. Expression of ER and EGFR protein was increased by TAM in the estrogen-completed mice, however it was decreased by TAM in the estrogen-depleted mice. Changes of ER and EGFR protein levels were similar in all treatments. Transforming growth factor-alpha (TGF-alpha) in tumors, which is known as a ligand of EGFR and as an estrogen-inducible protein in ER positive MCF-7 cells, was decreased by TAM in the estrogen-completed mice, by contrast, it was increased by TAM in the estrogen-depleted mice. Downregulation of ER was observed in TAM-treated mice in an estrogen-depleted environment, this action of TAM was similar to E2. These results suggest that increase of EGFR expression does not lead to a loss of ER after short-term TAM treatment in MCF-7 tumors.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , ErbB Receptors/analysis , Estradiol/pharmacology , Mammary Neoplasms, Experimental/drug therapy , Receptors, Estrogen/analysis , Tamoxifen/therapeutic use , Animals , Female , Humans , Mammary Neoplasms, Experimental/chemistry , Mice , Mice, Inbred BALB C , Mice, Nude , Neoplasm Transplantation , Transforming Growth Factor alpha/analysis , Transplantation, Heterologous
19.
Oncology ; 57 Suppl 2: 37-44, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10545801

ABSTRACT

The mitogen-activated protein (MAP) kinase is considered to play a central role in diverse cellular events including carcinogenesis and tumor progression. Indeed, expression of MAP kinase, tyrosine-phosphorylated MAP kinase, and Raf-1 protein was greater in cancerous human tissues than in the surrounding noncancerous glands. In a 7,12-dimethylbenz[a]anthracene-induced rat mammary carcinoma model, estrogen promoted and ovariectomy and antiestrogen, tamoxifen (TAM) inhibited the tumor growth. Ovariectomy suppressed expression of MAP kinase, tyrosine-phosphorylated MAP kinase and Raf-1, whereas estrogen as well as TAM induced expression of MAP kinase and Raf-1 under castrated conditions. Since it was reported that MAP kinase was activated during the progression of breast carcinoma cells, such estrogenic actions of TAM toward the MAP kinase cascade might be responsible for malignant progression.


Subject(s)
Breast Neoplasms/metabolism , Mitogens/metabolism , Protein Kinases/metabolism , Animals , Antineoplastic Agents, Hormonal/pharmacology , Breast Neoplasms/enzymology , Estrogen Receptor Modulators/pharmacology , Estrogens/metabolism , Female , Humans , Mammary Neoplasms, Experimental/metabolism , Protein Kinases/drug effects , Proto-Oncogene Proteins c-raf/metabolism , Rats , Tamoxifen/pharmacology
20.
Jpn J Cancer Res ; 90(6): 607-13, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10429651

ABSTRACT

A case-control study was conducted in Miyagi and Gunma prefectures, Japan, to evaluate the effectiveness of breast cancer screening by clinical breast examination (CBE) alone in reducing breast cancer mortality. Case subjects, who were female and had died of breast cancer, were collected from residential registry files and medical records. Control subjects matched in sex, age and residence were randomly selected from residential registry files. The screening histories during 5 years prior to the cases having been diagnosed as breast cancer were surveyed using the examinee files of the screening facilities. Finally, the data of 93 cases and 375 controls were analyzed. The odds ratio (OR) of breast cancer death for participating in screening at least once during 5 years was 0.93 (95% confidence interval (95% CI) 0.48-1.79). The cases were more symptomatic than the controls when screened. If the participants who had had symptoms in their breasts were classified as not screened, the OR decreased to 0.56 (95% CI 0.27-1.18). The case control study suggests that the current screening modality (CBE) lacks effectiveness (OR = 0.93), although it might be effective for an asymptomatic population (OR = 0.56). The number of cases was small, and a larger case-control study is desirable to define whether CBE is effective or not. However, it is necessary to consider the introduction of mammographic screening to reduce breast cancer mortality in Japan.


Subject(s)
Breast Neoplasms/diagnosis , Palpation , Adult , Aged , Aged, 80 and over , Case-Control Studies , Female , Humans , Japan , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...